Peptides and methods of use thereof, are disclosed for use in treating various diseases and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The peptides modulate the activity of the transcription factor NF κB.

Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): ##STR00001##
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R.sup.1, L.sup.1, L.sup.2, G, M, Y.sup.1 Y.sup.2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.

Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): ##STR00001##
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R.sup.1, L.sup.1, L.sup.2, G, M, Y.sup.1 Y.sup.2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.

Two synthetic tetrapeptides having a high binding affinity to human muscular nicotinic acetylcholine receptor (HmnAChR) are provided. A composition for inhibiting contraction of muscle cells is also provided. The composition comprises an effective amount of one of these two peptides. Also provided is a method for inhibiting contraction of muscle cells, which method comprises treating muscle cells with an effective amount of the composition. Further provided is a method for inducing proliferation of epidermal cells, which method comprises treating the epidermal cells with an effective amount of the composition. The epidermal cells may be human epidermal keratinocytes (HEKs).

Two synthetic tetrapeptides having a high binding affinity to human muscular nicotinic acetylcholine receptor (HmnAChR) are provided. A composition for inhibiting contraction of muscle cells is also provided. The composition comprises an effective amount of one of these two peptides. Also provided is a method for inhibiting contraction of muscle cells, which method comprises treating muscle cells with an effective amount of the composition. Further provided is a method for inducing proliferation of epidermal cells, which method comprises treating the epidermal cells with an effective amount of the composition. The epidermal cells may be human epidermal keratinocytes (HEKs).

The present disclosure provides multifunctional nanoparticles. More particularly, the present disclosure relates to multifunctional nanoparticles having one or more of nucleic acid ligands; and methods of using such nanoparticles for treatment and/or diagnosis of diseases and conditions.

Peptides and methods of use thereof, are disclosed for use in treating various disease and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The Peptides modulate the activity of the transcription factor NF κB.

Peptides and methods of use thereof, are disclosed for use in treating various disease and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The Peptides modulate the activity of the transcription factor NF κB.

AT-rich interactive domain-containing protein 5a (Arid5a) inhibitors can include mid-sized peptides (peptides having less than 15 amino acids) that inhibit the activity of Arid5a. The peptides include the sequence of SEQ ID NO: 1. In an embodiment, the Arid5a peptide inhibitors can include a peptide having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:3, and SEQ ID NO:4. The Arid5a peptide inhibitors can be useful for experimental investigation and treating a disease or disorder, such as, inflammation, diseases associated with inflammation, cancer, and autoimmune disease.

AT-rich interactive domain-containing protein 5a (Arid5a) inhibitors can include mid-sized peptides (peptides having less than 15 amino acids) that inhibit the activity of Arid5a. The peptides include the sequence of SEQ ID NO: 1. In an embodiment, the Arid5a peptide inhibitors can include a peptide having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:3, and SEQ ID NO:4. The Arid5a peptide inhibitors can be useful for experimental investigation and treating a disease or disorder, such as, inflammation, diseases associated with inflammation, cancer, and autoimmune disease.